Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
61.11B
Market cap61.11B
Price-Earnings ratio
14.57
Price-Earnings ratio14.57
Dividend yield
0.46%
Dividend yield0.46%
Average volume
1.00M
Average volume1.00M
High today
$582.00
High today$582.00
Low today
$574.23
Low today$574.23
Open price
$579.98
Open price$579.98
Volume
612.55K
Volume612.55K
52 Week high
$991.24
52 Week high$991.24
52 Week low
$476.49
52 Week low$476.49

REGN News

Nasdaq 8h
Benjamin Graham Detailed Fundamental Analysis - REGN

Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...

Benjamin Graham Detailed Fundamental Analysis - REGN
Simply Wall St 3d
Is Regeneron a Potential Bargain After 43% Drop and Strong 2025 Cash Flow Prospects?

Thinking about what to do with your Regeneron Pharmaceuticals shares? Or maybe you are wondering if now is the right time to jump in? You are not alone. Regener...

Is Regeneron a Potential Bargain After 43% Drop and Strong 2025 Cash Flow Prospects?
TipRanks 4d
Regeneron’s Cemiplimab Study: Real-World Insights and Market Impact

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...

Analyst ratings

76%

of 29 ratings
Buy
75.9%
Hold
20.7%
Sell
3.4%

More REGN News

Nasdaq 5d
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)

Regeneron Pharmaceuticals, Inc. REGN announced updated data on its investigational gene therapy DB-OTO from the CHORD study. This gene therapy is being evaluat...

REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
TipRanks 6d
Regeneron announces new, updated data from oncology pipeline

Regeneron (REGN) Pharmaceuticals announced new and updated data from its advancing oncology pipeline will be shared in seven abstracts at the European Society f...

TipRanks 6d
Regeneron Faces Declining Eylea Sales and Medicare Risks, Justifying Sell Rating

Bank of America Securities analyst Tim Anderson reiterated a Sell rating on Regeneron today and set a price target of $543.00. Elevate Your Investing Strategy:...

Barchart 6d
Regeneron’s Q3 2025 Earnings: What to Expect

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. ( REGN ) is a biotechnology company that invents, develops, manufactures, and commercializes medicines...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.